ArticleOPEN ACCESS

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: A retrospective study

Cancer Communications
DOI: 10.1186/s40880-019-0405-5
16Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Cai, W., Cai, B., Zhou, J., Chen, Y., Zhang, J., Huang, Y., … Huang, J. (2019, October 11). Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: A retrospective study. Cancer Communications. BioMed Central Ltd. https://doi.org/10.1186/s40880-019-0405-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free